PE-22-28 from Super Human Peptides UK is a highly stable, synthetic heptapeptide (7-amino acid sequence: Gly-Val-Ser-Trp-Gly-Leu-Arg). It is an engineered derivative of Spadin, an endogenous peptide known for its mood-regulating properties. In laboratory research, PE-22-28 is studied as a highly selective inhibitor of the TREK-1 two-pore-domain potassium channel.
Unlike traditional research models utilizing SSRIs (which target serotonin transporters), researchers utilize PE-22-28 to investigate an entirely different pathway for neurogenesis and synaptogenesis. Produced under GMP-compliant conditions and verified for 99% purity or higher, PE-22-28 is a cutting-edge tool for preclinical models exploring rapid-onset antidepressant effects, stroke recovery, and the restoration of hippocampal plasticity.
WarningFor laboratory research use only. Not for human consumption.
Key Features
- —TREK-1 Inhibitor: Highly selective antagonist for the K2P2.1 potassium channel.
- —Spadin Analogue: Engineered for significantly greater stability and a longer half-life than natural Spadin.
- —Rapid Neurogenesis: Studied for its ability to induce measurable hippocampal changes in a fraction of the time required by standard monoamine agents.
- —High Purity: 99% purity or higher (verified by HPLC and MS analysis).
- —Quality Standard: GMP / ISO certified manufacturing.
- —Documentation: Full Certificate of Analysis (COA) included with every batch.
Research Focus
- —Potassium Channel Blockade: Studying the specific inhibition of TREK-1 and its downstream effects on neuronal excitability.
- —Rapid Synaptogenesis: Measuring increases in Postsynaptic Density Protein 95 (PSD-95) expression in cortical neurons.
- —Hippocampal Neurogenesis: Researching the proliferation of new neurons in the brain's memory and emotion centers.
- —Ischemia and Stroke Recovery: Preclinical models investigating the peptide's ability to reduce apoptotic cell death and cognitive defects following stroke.
- —Behavioral Despair Models: Evaluating the reduction of immobility times in standard laboratory stress tests (e.g., forced swim tests).
Published Research and Study Findings
PE-22-28 was developed by researchers seeking a more stable alternative to Spadin. A landmark study by Djillani et al. (2017) demonstrated that PE-22-28 displayed significantly better specificity and affinity for the TREK-1 channel than its parent molecule (an IC50 of 0.
12 nM vs. 40-60 nM for Spadin). Most notably, laboratory models indicate that the onset of action for PE-22-28 is exceptionally rapid.
While traditional neurogenic agents often take weeks to show physical changes in the brain, animal models treated with PE-22-28 demonstrated significant neurogenesis and synaptogenesis after just four days of administration. Furthermore, its biological half-life was shown to be vastly improved over natural Spadin, making it a highly viable candidate for prolonged neuroprotection and mood-regulation research.
NoteAll findings are derived from laboratory and non-clinical research settings.
Representative Scientific References
- 1.Djillani, A. et al., "Shortened Spadin Analogs Display Better TREK-1 Inhibition, In Vivo Stability and Antidepressant Activity," Frontiers in Pharmacology, 2017.
- 2.Mazella, J. et al., "Spadin, a sortilin-derived peptide, targeting rodent TREK-1 channels: a new concept in the antidepressant drug design," PLoS Biology, 2010. Moha Ou Maati, H. et al., "Activation of TREK-1 by spadin-analogs," Neuropharmacology, 2012.
